Danish drug maker Novo Nordisk has struck partnerships with 10 Indian artificial intelligence (AI) startups to streamline its ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

Thermo Fisher Scientific is responsible for helping to produce some of the hottest drugs on the market, including Novo ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...

Weight-loss medications like the popular versions made by Denmark's Novo Nordisk A/S (CSE:NOVOb) and US peer Eli Lilly ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

France has refused to endorse prescribing weight loss drug, Wegovy through its national insurance system, despite being on ...

Ozempic, Wegovy, and Eli Lilly And Co's (NYSE:LLY) Mounjaro and Zepbound have fueled an illicit market of counterfeit and ...

Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week. Wegovy has been FDA-approved ...

As the obesity clinical trials evolve, there is a growing emphasis on how decentralisation and new technologies can play a ...